Recent Publications by Alexion Pharmaceuticals Incorporated: |
Importance of technical operations: lessons from evolving biotherapeutics production methods.
Research and development connect technology and innovation to product... | 22nd September, 2009
| Fermentation and Cell Culture Development, Technical Operations, Alexion
| Trends Biotechnol. 2009 Nov;27(11):612-4. Epub 2009 Sep 16.
DOI Direct Link |
Kinetic analysis of a monoclonal therapeutic antibody and its single-chain homolog by surface plasmon resonance.
Monoclonal antibodies (mAbs) and antibody fragments have become an... | 2nd September, 2009
| Alexion Pharmaceuticals, Cheshire, CT 06410, USA.
| Anal Biochem. 2009 Aug 29.
DOI Direct Link |
C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients.
We explored whether a functionally blocking anti-C5 monoclonal antibody... | 4th July, 2008
| Alexion Pharmaceuticals, Inc., Cheshire, CT, USA.
| Am J Transplant. 2008 Jun;8(6):1129-42. Epub 2008 Apr 29.
DOI Direct Link |
Characterization of cartilage from H-transferase transgenic pigs.
Cartilage engineering is the object of intense research as a result of... | 25th June, 2008
| Department of Molecular Sciences, Alexion Pharmaceuticals, Inc, Cheshire,
| Transplant Proc. 2008 Mar;40(2):554-6.
DOI Direct Link |
Mass spectrometry and HPLC with fluorescent detection-based orthogonal approaches to characterize N-linked oligosaccharides of recombinant monoclonal antibodies.
A number of HPLC and mass spectrometric techniques are used to... | 5th June, 2008
| Alexion Pharmaceuticals, Cheshire, CT, USA.
| Methods Mol Biol. 2008;446:347-61.
DOI Direct Link |
Comparability and monitoring immunogenic N-linked oligosaccharides from recombinant monoclonal antibodies from two different cell lines using HPLC with fluorescence detection and mass spectrometry.
One of the most important structural features of recombinant monoclonal... | 5th June, 2008
| Alexion Pharmaceuticals, Cheshire, CT, USA.
| Methods Mol Biol. 2008;446:333-46.
DOI Direct Link |
Monitoring glycosylation of therapeutic glycoproteins for consistency by HPLC using highly fluorescent anthranilic acid (AA) tag.
Majority of protein drugs in development today are glycoproteins e.g.... | 5th June, 2008
| Alexion Pharmaceuticals, Cheshire, CT, USA.
| Methods Mol Biol. 2008;446:317-31.
DOI Direct Link |
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
The complement system provides critical immunoprotective and... | 29th February, 2008
| Alexion Pharmaceuticals, Inc., 352 Knotter Drive, Cheshire, Connecticut
| Nat Biotechnol. 2007 Nov;25(11):1256-64.
DOI Direct Link |
Characterization of porcine tumor necrosis factor receptor 2: implications for xenotransplantation.
Clinical solid organ xenotransplantation is precluded by the strong immune... | 14th November, 2007
| Department of Molecular Sciences, Alexion Pharmaceuticals Inc, Cheshire,
| Transplant Proc. 2007 Sep;39(7):2443-6.
DOI Direct Link |
Role of complement component C5 in cerebral ischemia/reperfusion injury.
We evaluated the role of complement component C5 during the course of... | 19th September, 2006
| Department of Preclinical Sciences, Alexion Pharmaceuticals Inc.,
| Brain Res. 2006 Jul 19;1100(1):142-51. Epub 2006 Jun 15.
DOI Direct Link |
Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response.
The role of complement component C5 in asthma remains controversial. Here... | 12th August, 2005
| Alexion Pharmaceuticals Inc., Cheshire, Connecticut 06410, USA.
| J Clin Invest. 2005 Jun;115(6):1590-600. Epub 2005 May 12.
DOI Direct Link |
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.
CONTEXT: The efficient sequestration of hemoglobin by the red blood cell... | 12th April, 2005
| Alexion Pharmaceuticals,
| JAMA. 2005 Apr 6;293(13):1653-62.
DOI Direct Link |
Use of porcine tumor necrosis factor receptor 1-Ig fusion protein to prolong xenograft survival.
BACKGROUND: Delayed rejection of xenografts is a major hurdle that needs... | 5th March, 2005
| Department of Molecular and Preclinical Sciences, Alexion Pharmaceuticals
| Xenotransplantation. 2004 Nov;11(6):491-502.
DOI Direct Link |
Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.
The importance of the complement system in the pathophysiology of systemic... | 14th January, 2005
| Alexion Pharmaceuticals Inc., Chesire, CT 06410, USA.
| Lupus. 2004;13(5):328-34.
|
CD86 blockade in genetically modified porcine cells delays xenograft rejection by inhibiting T-cell and NK-cell activation.
Porcine xenografts transplanted into primates are rejected in spite of... | 6th October, 2004
| Department of Molecular Science, Alexion Pharmaceuticals Inc., 352 Knotter
| Cell Transplant. 2004;13(1):75-87.
|
